Codexis, Inc.

Margie Tabuga Borra-Garske

Oscar Alvizo

Agustina Rodriguez-Granillo

Anna Fryszkowska

Aksiniya Lyubenova Petkova

Lillian Jasmine Miller

Jovana Nazor

Nicholas M Marshall

Deeptak Verma

Harvinder Chagger Maniar

Nandhitha Subramanian

Christopher Michael Micklitsch

Mikayla Jianghongxia Krawczyk

Dewan Andrews

Melissa Ann Mayo

Stephan Jenne

Carmela Molinaro

Grant S Murphy

Auric Anthony Sowell-Kantz

Joshua N Kolev

Jesse B Slaton

The present invention provides engineered galactose oxidase (GOase) enzymes, polypeptides having GOase activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing GOase enzymes are also provided. The present invention further provides compositions comprising the GOase enzymes and methods of using the engineered GOase enzymes. The present invention finds particular use in the production of pharmaceutical and other compounds.

Engineered galactose oxidase variant enzymes

The present invention provides engineered acetate kinase (AcK) enzymes, polypeptides having AcK activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing AcK enzymes are also provided. The present invention further provides compositions comprising the AcK enzymes and methods of using the engineered AcK enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Polynucleotides encoding engineered acetate kinase variant enzymes

Cyclic GMP-AMP synthase (cGAS) enzymes have been engineered to produce polypeptides having increased cGAS activity in the cyclization of modified nucleoside triphosphates, including thiolated or fluorinated nucleoside triphosphates, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing cGAS enzymes, compositions comprising the cGAS enzymes, and methods of using the engineered cGAS enzymes are useful for the production of pharmaceutical compounds.

Engineered cyclic GMP-AMP synthase (cGAS) variant enzymes

The present invention provides engineered pantothenate kinase (PanK) enzymes, polypeptides having PanK activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PanK enzymes are also provided. The present invention further provides compositions comprising the PanK enzymes and methods of using the engineered PanK enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Engineered pantothenate kinase variant enzymes

The present application provides engineered polypeptides having imine or oxime reductase activity, polynucleotides encoding the engineered polypeptides, host cells capable of expressing the engineered polypeptides, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Engineered imine reductases and methods for the reductive amination of ketone and amine compounds

Engineered acetate kinase variant enzymes

The present application provides engineered polypeptides having imine or oxime reductase activity, polynucleotides encoding the engineered polypeptides, host cells capable of expressing the engineered polypeptides, and methods of using these engineered polypeptides with a range of ketone amine substrate compounds to prepare secondary and tertiary amine product compounds.

Growing community of inventors

Palo Alto, CA, United States of America

Margie Tabuga Borra-Garske